Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.51 |
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709500 | 1.00 | ALDH1A1 (0.51) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL11987771 | 0.99 | ALDH1A1 (0.51) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1205527 | 0.82 | ALDH1A1 (0.49) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL105072 | 0.81 | DHPS (0.50) | ALDH1A1RAB9ABTKLMNASTAT1 | |
| SCHEMBL18130771 | 0.81 | ALDH1A1 (0.42) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL21452323 | 0.80 | BRD4 (0.42) | ALDH1A1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL1204429 | 0.80 | ALDH1A1 (0.52) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL28928116 | 0.79 | ALDH1A1 (0.59) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL9985857 | 0.78 | RAB9A (0.51) | ALDH1A1RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL29782491 | 0.76 | BTK (0.46) | RAB9ASMN1; SMN2NPC1MAPTBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-113583007-A | Pyrrolopyrimidine BTK inhibitor and preparation method and application thereof | 山东大学 | 2021-11-02 | — | — | CN | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| EP-3483167-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3013337-B1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2188267-B1 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | GILEAD CONNECTICUT INC (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | ALDH1A1 2556/4885RAB9A 2778/4885SMN1; SMN2 3588/4885 |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | ALDH1A1 2557/4885RAB9A 2208/4885SMN1; SMN2 4120/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | ALDH1A1 3990/4885RAB9A 1663/4885SMN1; SMN2 4495/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | ALDH1A1 3686/4885RAB9A 3055/4885SMN1; SMN2 3454/4885 |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | ALDH1A1 2557/4885RAB9A 2208/4885SMN1; SMN2 4120/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | ALDH1A1 3393/4885RAB9A 2467/4885SMN1; SMN2 3343/4885 |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | ALDH1A1 2557/4885RAB9A 2208/4885SMN1; SMN2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.